Definitive Contract 75A50119C00037
Award Date
5/31/19
Potential Completion Date
5/30/29
Potential Value
$601M
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
2323 Riverside Dr., Ottawa, ON K1H 1A1, Canada
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded an Other Transaction Agreement to Emergent Biosolutions Canada Inc. valued at $34.6 million to support the development of human immune globulin (COVID-HIG) manufactured from human plasma with antibodies to SARS-CoV-2. The contract aims to prevent coronavirus disease (COVID-19) through October 2022. Performance will take place at Emergent Biosolutions Canada Inc.'s facility in Ottawa,...
This is a $748,857,151.46 firm fixed-price contract awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Product Development Gaithersburg Inc., a for-profit manufacturer, to develop and deliver the ACAM2000 smallpox (vaccinia) vaccine over a 10-year period. The contract was awarded on a sole-source basis as Emergent is the only FDA-licensed provider of ACAM2000. This contract does not have a set-aside...
This contract award, valued at $37,890,000, was issued by the Centers for Disease Control and Prevention (CDC) to Emergent BioDefense Operations Lansing LLC for the delivery of ACAM 2000 vaccines. ACAM 2000 is the only Food and Drug Administration (FDA)-licensed vaccine for the prevention of smallpox disease, a critical component of the U.S. government's strategic national stockpile. The contract, awarded on September 30, 2015, is a firm-fixed-price delivery order with an ultimate completion...
This firm fixed-price contract, valued at $762,812,695, was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) to Emergent Product Development Gaithersburg Inc., a for-profit limited liability company. The contract is for the development of medical countermeasures (MCM) that can be deployed in the event of a filovirus outbreak, which is a crucial component of the U.S. government's outbreak response...
This is a firm fixed-price delivery order awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Glaxosmithkline, LLC, a pharmaceutical company that provides vaccines, antivirals, and other pharmaceutical products to U.S. government agencies. The $15,769,590.00 contract is for commercial bulk lots, with no set-aside designation, and is part of the Pandemic Influenza Preparedness and Response 2016-2021 IDIQ contract. The...
This is a $1,403,362,669.10 cost-plus-fixed-fee contract awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Product Development Gaithersburg Inc., a for-profit limited liability company manufacturing medical countermeasures and pharmaceuticals. The contract, which has a period of performance through September 29, 2026, is for the development of filovirus treatments. Emergent has received over $1.3...
This is a $533,988.00 firm fixed price delivery order awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to the pharmaceutical company Glaxosmithkline, LLC. The contract is part of the Pandemic Influenza Preparedness and Response 2012-2016 IDIQ, which provides for the acquisition of medical countermeasures for pandemic influenza preparedness and response efforts. The contract does not have a set-aside designation....
<p>This is a contract awarded by the Department of Health and Human Services (HHS) Centers for Disease Control and Prevention (CDC) to Emergent Biodefense Operations Lansing LLC, also known as Emergent Biodefense, for the maintenance of a smallpox license. The contract is a delivery order with a firm fixed price of $38,430,000.00 and a completion date of January 31, 2019. The place of performance is located in Cambridge, Massachusetts. The contract does not have a set-aside designation.</p>
This is a firm fixed price delivery order contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Sanofi Pasteur Inc., a foreign-owned, for-profit manufacturer of goods. The contract has a potential value of $339,189.20 and is under a larger Indefinite Delivery Vehicle (IDV) contract named "Pandemic Influenza Preparedness and Response 2016-2021" with a potential value up to $5.87 billion. This contract...
This is a $50,556,695.00 definitive contract awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a pharmaceutical company that provides vaccines, antiviral medications, and other pharmaceutical products to U.S. government agencies. The contract, titled "2016 VFA - GSK", is for a firm fixed price and has an ultimate completion date of June 30, 2017. It is not a set-aside contract. Glaxosmithkline has provided a range of pharmaceutical goods and...